Project Grant R21CA307817
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $466K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- The National Cancer Institute awarded Weill Medical College of Cornell University $716,183 on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate and target co-inhibitory and co-stimulatory molecules in CAR T-cell therapies. The award funds research to overcome clinical barriers in adoptive cell therapies with chimeric antigen receptors, which show promise for cancer treatment but face challenges including insufficient T-cell persistence, antigen escape, and...
- The National Cancer Institute awarded Weill Medical College of Cornell University $435,827 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop autologous lymph node T cells engineered to overcome treatment-resistant lung cancer. The research addresses the limited effectiveness of adoptive T-cell therapy in solid tumors by utilizing polyclonal cohorts of multipotent T cells derived from tumor-draining lymph nodes rather than peripheral blood. Prior work...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $452,540 on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the innate and adaptive immune determinants of cytokine release syndrome (CRS) following chimeric antigen receptor (CAR) T cell therapy. CRS occurs in approximately 93 percent of patients receiving CAR T cell therapy, manifesting as fever, hypotension, hypoxia, and dyspnea due to rapid increases in multiple cytokines...
- The National Cancer Institute awarded Weill Medical College of Cornell University $733,149 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate immune-related adverse events (IRAE) driven by anti-PD1 immunotherapy in cancer patients. The research integrates patient-centered clinical investigation with advanced omics pipelines using human specimens, leveraging a multidisciplinary approach spanning human and mouse tissue and tumor immunology. The...
- The National Cancer Institute awarded Weill Medical College of Cornell University $703,423 on a Project Grant (R01CA306020) effective June 1, 2026 under the Cancer Biology Research program (CFDA 93.396). The award funds research to identify molecular targets for mitigating immune-related adverse events (IRAEs) triggered by immunotherapy, particularly immune checkpoint blockade agents used in cancer treatment. IRAEs occur in 20–30 percent of cancer patients receiving these agents, with skin and...
- The National Cancer Institute awarded Mayo Clinic $685,116 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of interleukin-5 (IL-5) in chimeric antigen receptor T cell immunotherapy for cancer. The project addresses treatment failure and toxicity in CAR T cell therapy, which has achieved FDA approval in relapsed or refractory hematological cancers but shows high relapse rates within two years and significant adverse effects including...
- The National Cancer Institute awarded Weill Medical College of Cornell University $694,133 on May 14, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate how sympathetic nervous system axons control melanoma progression and interact with immune effectors in the tumor microenvironment. The research focuses on defining the role of sympathetic axons in inhibiting melanoma growth through norepinephrine signaling via adrenergic receptors on immune cells, particularly...
- The National Cancer Institute awarded $435,243 to Weill Medical College of Cornell University on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate GSK3 relocalizing peptides as anti-cancer therapeutics. The recipient will assess the anti-cancer efficacy of GSK3 RNLS-peptide both as a standalone therapy and in combination with the chemotherapeutic agent 5-fluorouracil. The work employs multiple orthotopic mouse models of lung, brain, and colorectal...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $671,252 on July 1, 2026, under Cancer Biology Research (CFDA 93.396) to investigate CD4 T cell and dendritic cell interactions that license CD8 T cell cytotoxicity against tumor cells. The research examines how tumor-specific CD4 T cells, CD8 T cells, and dendritic cells form three-cell clusters (triads) within tumors to overcome CD8 T cell dysfunction and exhaustion. Prior work by the recipient demonstrated...
- The National Cancer Institute awarded The Washington University $548,528 under the Cancer Treatment Research program (CFDA 93.395) on September 3, 2026, to enhance CAR-T cell therapy for relapsed or refractory large B cell lymphoma. The recipient will conduct a Phase 1B clinical trial evaluating early and repeated dosing schedules of NT-I7, a long-acting interleukin-7 therapeutic, administered following axicabtagene ciloleucel or lisocabtagene maraleucel infusion in patients with relapsed or...